The flavonoid quercetin is a BACE1 inhibitor that exhibits novel pharmacophore features for AD45, as well as an inhibitor for AChE (IC50 = 19.8 μM)46 with a negligible influence on BChE activity47; moreover, it effectively ameliorated AD pathology and tauopathy and protected cognitive and emotional functions in aged (21–24 months old) triple transgenic mouse models of AD (3xTg-AD) treated with 25 mg/kg via i.p. injection every 48 h for 3 months48. Here, BACE1 is linked to tauopathy.